Advances in Biologics and CGT

September 28, 5 - 7:30pm EDT | Cambridge, MA

We are excited to share that we will be joining the Advances in Biologics and CGT Networking Reception hosted by Catalent. This event will bring C-suite executives, and venture capital investors for an invite only Happy Hour at Cambridge’s Biotech hub.

Sean Forestell, Director, CMC Operations of Alira Health will be joining a discussion “Unveiling Biologic and Cell & Gene Therapy Market Trends” among other industry experts, uncovering the latest trends and advancements in the Biologics and Cell & Gene Therapy markets.

If you would like to take a deeper dive into the rapidly growing global Biologics and Advanced Therapies market, download our latest 2023 Biologics and Advanced Therapies Contract Manufacturing Report.


Our Speaker
Published on:
September 27, 2023
Sean Forestell

Sean Forestell

Director, CMC Operations Sean Forestell, Ph.D. is an expert in biologics process development and manufacturing with over 30 years of experience in the biotech industry, including senior leadership roles at BioMarin, Genentech, and Novartis. Dr. Forestell’s broad experience includes viral vectors used in cell and gene therapy, monoclonal antibodies, and enzymes to treat ultra rare diseases that are produced using continuous manufacturing technologies. He has been involved in the successful technology transfer of 12 early-stage clinical products and four successful process performance qualifications (PPQs), and has supported the manufacture of eight different commercial products. Dr. Forestell earned a B.Sc. in biological engineering at the University of Guelph and a Ph.D. in chemical engineering from the University of Calgary. He has co-authored 19 articles in peer-reviewed journals and is an inventor on two issued patents.

Related news

Publications November 20, 2023
Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges
Our experts conducted a deep evaluation of IgG-like bsAbs including general advantages and disadvantages compared with MAbs and more.
Publications November 20, 2023
Immunoglobulin Fc-Fusion Proteins
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing(...)
Publications November 14, 2023
Capture of CH1-Containing Bispecific Antibodies: Evaluating an Alternative to Protein A
In the article our team investigated the use of an alternative purification method for BsAbs – a commercially available CaptureSelect CH1-XL affinity resin.
CMC Drug Development
Multimedia October 18, 2023
The Process of CDMO Selection for Antibody Development: Matching Capabilities to Need
In this webinar, you'll learn how to identify key solution features, define patient experience expectations, generate evidence, and more!
Events September 27, 2023
Advances in Biologics and CGT
We are excited to share that we will be joining the Networking Reception: Advances in Biologics and CGT hosted by Catalent.
Biologics CMC
Publications September 21, 2023
Essential Elements of Technology Transfer
Peter Alexander, Senior Consultant, CMC, co-authored an article about technology transfer categories, essential elements, and documentation.
Publications September 20, 2023
Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates
Our expert CMC team addresses the manufacturing challenges of ADCs in “Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates.”
CMC Drug Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.